新冠疫情期间阿片类使用障碍远程医疗与药物治疗同致命药物过量的关联
该队列研究基于美国联邦医疗保险按服务收费受益人数据,比较疫情前与疫情期间启动阿片类使用障碍(OUD)相关照护的两组人群。疫情期间接受OUD相关远程医疗服务、阿片类使用障碍药物治疗(MOUD)——尤其是阿片类治疗项目提供的MOUD及门诊丁丙诺啡——与致命药物过量风险降低相关,而门诊缓释纳曲酮未见此关联。
要点
- 疫情期间OUD相关远程医疗服务与致命药物过量风险降低相关(aOR 0.67)。
- 阿片类治疗项目提供的MOUD与致命药物过量风险降低相关(aOR 0.41)。
- 门诊丁丙诺啡与致命药物过量风险降低相关(aOR 0.62),门诊缓释纳曲酮无此关联。
核心结论
- 在疫情期间启动OUD相关照护的联邦医疗保险受益人中,接受OUD相关远程医疗服务与致命药物过量风险降低相关。
- 接受阿片类治疗项目提供的MOUD及门诊丁丙诺啡也与致命药物过量风险降低相关。
- 门诊缓释纳曲酮与致命药物过量风险降低无显著关联。
研究设计与样本
- 该研究为队列研究,使用探索性纵向数据,纳入两个队列:疫情前队列(2018年9月1日至2020年2月29日)和疫情期间队列(2019年9月1日至2021年2月28日)。
- 研究对象为18岁及以上、启动OUD相关照护的联邦医疗保险按服务收费受益人,数据来自美国联邦医疗保险与医疗补助服务中心及美国疾病控制与预防中心国家死亡指数。
主要发现
- 疫情期间队列全因死亡率高于疫情前队列(每1000名受益人99.9例死亡 vs 76.8例死亡,P < .001)。
- 疫情期间队列致命药物过量发生率高于疫情前队列(每1000名受益人5.1例 vs 3.7例,P < .001)。
- 两队列中致命药物过量死亡占全部死亡的比例相似(疫情前4.8% vs 疫情期间5.1%,P = .49)。
关键数值与推荐
- 在疫情期间队列的多变量分析中,接受OUD相关远程医疗服务与致命药物过量风险降低相关(aOR 0.67;95% CI 0.48-0.92)。
- 接受阿片类治疗项目提供的MOUD与致命药物过量风险降低相关(aOR 0.41;95% CI 0.25-0.68)。
- 门诊环境下接受丁丙诺啡与致命药物过量风险降低相关(aOR 0.62;95% CI 0.43-0.91)。
- 门诊环境下接受缓释纳曲酮与致命药物过量风险降低无显著关联(aOR 1.16;95% CI 0.41-3.26)。
临床怎么用
- 在OUD照护中可考虑扩大远程医疗服务及MOUD(尤其是阿片类治疗项目提供的MOUD和门诊丁丙诺啡)的可及性。
- 需制定策略以扩大MOUD提供、提高治疗留存率,并处理共病的躯体与行为健康问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Federal emergency authorities were invoked during the COVID-19 pandemic to expand clinical telehealth for opioid use disorder (OUD). OBJECTIVE: To examine the association of the receipt of telehealth services and medications for OUD (MOUD) with fatal drug overdoses before and during the pandemic. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used exploratory longitudinal data from 2 cohorts (prepandemic cohort: September 1, 2018, to February 29, 2020; pandemic cohort: September 1, 2019, to February 28, 2021) of Medicare Fee-for-Service beneficiaries aged 18 years or older initiating an episode of OUD-related care using Medicare Fee-for-Service data from the Centers for Medicare & Medicaid Services and National Death Index data from the Centers for Disease Control and Prevention. Data analysis was performed from September 19 to October 17, 2022. EXPOSURES: Prepandemic vs pandemic cohort demographic, medical, substance use, and psychiatric characteristics. MAIN OUTCOMES AND MEASURES: Receipt of OUD-related telehealth services, receipt of MOUD, and fatal drug overdose. RESULTS: The prepandemic cohort comprised 105 162 beneficiaries (58.1% female; 67.6% aged 45-74 years). The pandemic cohort comprised 70 479 beneficiaries (57.1% female; 66.3% aged 45-74 years). The rate of all-cause mortality was higher in the pandemic cohort (99.9 per 1000 beneficiaries; 7041 deaths) than in the prepandemic cohort (76.8 per 1000; 8076 deaths) (P < .001). The rate of fatal drug overdoses was higher in the pandemic cohort (5.1 per 1000 beneficiaries; n = 358) than in the prepandemic cohort (3.7 per 1000; n = 391) (P < .001). The percentage of deaths due to a fatal drug overdose was similar in the prepandemic (4.8%) and pandemic (5.1%) cohorts (P = .49). In multivariable analysis of the pandemic cohort, receipt of OUD-related telehealth was associated with a significantly lower adjusted odds ratio (aOR) for fatal drug overdose (aOR, 0.67; 95% CI, 0.48-0.92) as was receipt of MOUD from opioid treatment programs (aOR, 0.41; 95% CI, 0.25-0.68) and receipt of buprenorphine in office-based settings (aOR, 0.62; 95% CI, 0.43-0.91) compared with those not receiving MOUD; receipt of extended-release naltrexone in office-based settings was not associated with lower odds for fatal drug overdose (aOR, 1.16; 95% CI, 0.41-3.26). CONCLUSIONS AND RELEVANCE: This cohort study found that, among Medicare beneficiaries initiating OUD-related care during the COVID-19 pandemic, receipt of OUD-related telehealth services was associated with reduced risk for fatal drug overdose, as was receipt of MOUD from opioid treatment programs and receipt of buprenorphine in office-based settings. Strategies to expand provision of MOUD, increase retention in care, and address co-occurring physical and behavioral health conditions are needed.
引用
- Jones CM, Shoff C, Blanco C, et al. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic. JAMA Psychiatry. 2023. PMID: 36988913. doi:10.1001/jamapsychiatry.2023.0310
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。